{"id":4359,"date":"2020-07-20T19:23:55","date_gmt":"2020-07-20T17:23:55","guid":{"rendered":"http:\/\/silta.es\/juantatay\/?p=4359"},"modified":"2020-07-20T19:26:06","modified_gmt":"2020-07-20T17:26:06","slug":"betting-on-biotech-report-by-pitchbook","status":"publish","type":"post","link":"https:\/\/silta.es\/juantatay\/betting-on-biotech-report-by-pitchbook\/","title":{"rendered":"\u00abBetting on Biotech\u00bb report by @pitchbook"},"content":{"rendered":"
\n
\n
\n

Cultivating an understanding of the VC investment landscape of US-based\u00a0biotech & pharma startups.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

Origin:\u00a0PitchBook Analyst Note: Betting on Biotech<\/a><\/p>\n

\n
\n
\n

Key takeaways:<\/p>\n<\/div>\n<\/div>\n

\n
\n
    \n
  • Over the last few decades, the biotechnology & pharmaceuticals (biotech & pharma) industry has seen a shift from drug development through internal R&D efforts at large-cap public incumbents to an M&A-based model.<\/li>\n
  • The drug development lifecycle, characterized by clear intermittent milestones and long-payback periods with high upside, makes biotech startups uniquely positioned to receive illiquid VC investment.<\/li>\n
  • As VC biotech investing has evolved, three distinct models have emerged for commercializing new technologies.<\/li>\n
  • Biotech startups take a different funding trajectory than most VC- backed startups, raising larger sums more quickly.<\/li>\n<\/ul>\n<\/div>\n
    report here https:\/\/files.pitchbook.com\/website\/files\/pdf\/PitchBook_Q3_2020_Analyst_Note_Betting_on_Biotech.pdf<\/div>\n
    <\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Cultivating an understanding of the VC investment landscape of US-based\u00a0biotech & pharma startups. Origin:\u00a0PitchBook Analyst Note: Betting on Biotech Key takeaways: Over the last few decades, the biotechnology & pharmaceuticals (biotech & pharma) industry has seen a shift from drug development through internal R&D efforts at large-cap public incumbents to an M&A-based model. The drug […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[5,163,185,303,151,46,165,25],"tags":[305,219,207],"class_list":["post-4359","post","type-post","status-publish","format-standard","hentry","category-financial","category-funding","category-industry-data","category-investors","category-opinion","category-start-it-up","category-technology","category-tecnologia","tag-investors","tag-startups","tag-valuation"],"jetpack_featured_media_url":"","jetpack-related-posts":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/silta.es\/juantatay\/wp-json\/wp\/v2\/posts\/4359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/silta.es\/juantatay\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/silta.es\/juantatay\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/silta.es\/juantatay\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/silta.es\/juantatay\/wp-json\/wp\/v2\/comments?post=4359"}],"version-history":[{"count":3,"href":"https:\/\/silta.es\/juantatay\/wp-json\/wp\/v2\/posts\/4359\/revisions"}],"predecessor-version":[{"id":4362,"href":"https:\/\/silta.es\/juantatay\/wp-json\/wp\/v2\/posts\/4359\/revisions\/4362"}],"wp:attachment":[{"href":"https:\/\/silta.es\/juantatay\/wp-json\/wp\/v2\/media?parent=4359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/silta.es\/juantatay\/wp-json\/wp\/v2\/categories?post=4359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/silta.es\/juantatay\/wp-json\/wp\/v2\/tags?post=4359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}